A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA
Latest Information Update: 11 Oct 2024
At a glance
- Drugs Binimetinib (Primary) ; Encorafenib (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms STARBOARD
- Sponsors Pfizer
- 11 Feb 2024 This trial has been discontinued in Austria, according to European Clinical Trials Database record.
- 11 Feb 2024 This trial has been discontinued in Austria, according to European Clinical Trials Database record.
- 09 Feb 2024 This trial has been discontinued in Norway, according to European Clinical Trials Database record.